Dodecyl creatine ester therapy: from promise to reality

Area of Science:

• Genetics and Molecular Biology
• Neuroscience
• Pharmacology

Background:

• Pathogenic variants in SLC6A8 impair brain creatine uptake, causing creatine transporter deficiency (CTD).
• CTD is associated with intellectual disability, behavioral disorders, epilepsy, and speech/language delays.
• Currently, no effective treatments exist to improve neurodevelopmental outcomes in CTD patients.

Purpose of the Study:

• To review recent advancements in therapeutic molecules for CTD.
• To highlight dodecyl creatine ester as a promising drug candidate for treating CTD.

Main Methods:

• Literature review of recent research on CTD therapeutics.
• Focus on preclinical and clinical data for dodecyl creatine ester.

Main Results:

• Identification of innovative molecular strategies for CTD treatment.
• Dodecyl creatine ester demonstrates significant potential as a therapeutic agent.

Conclusions:

• There is a critical need for treatments for CTD.
• Dodecyl creatine ester represents a promising therapeutic avenue for improving neurodevelopmental outcomes in CTD.